ES2180417B1 - NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA. - Google Patents

NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.

Info

Publication number
ES2180417B1
ES2180417B1 ES200100592A ES200100592A ES2180417B1 ES 2180417 B1 ES2180417 B1 ES 2180417B1 ES 200100592 A ES200100592 A ES 200100592A ES 200100592 A ES200100592 A ES 200100592A ES 2180417 B1 ES2180417 B1 ES 2180417B1
Authority
ES
Spain
Prior art keywords
protein
overexpressed
new
cancer
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100592A
Other languages
Spanish (es)
Other versions
ES2180417A1 (en
Inventor
Timothy Thomson Okatsu
Patricia Benedit Hernandez
Kosanna Paciucci Barzanti
Joan Morote Robles
Jaume Reventos Puigjaner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTO CATALAN de la SALUD HOSP
Consejo Superior de Investigaciones Cientificas CSIC
Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Original Assignee
INSTO CATALAN de la SALUD HOSP
Consejo Superior de Investigaciones Cientificas CSIC
Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTO CATALAN de la SALUD HOSP, Consejo Superior de Investigaciones Cientificas CSIC, Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR filed Critical INSTO CATALAN de la SALUD HOSP
Priority to ES200100592A priority Critical patent/ES2180417B1/en
Priority to PCT/ES2002/000122 priority patent/WO2002072633A1/en
Publication of ES2180417A1 publication Critical patent/ES2180417A1/en
Application granted granted Critical
Publication of ES2180417B1 publication Critical patent/ES2180417B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

Nueva proteína sobreexpresada en cáncer de próstata. Un nuevo gen y proteína sobreexpresado en cáncer de próstata ha sido identificado y secuenciado. En la presente invención se demuestra que se sobreexpresa en adenocarcinoma de próstata mediante la técnica RT-PCR y western-blot. La expresión de esta proteína está correlacionada con la proliferación de tumores. Han sido generados anticuerpos específicos que detectan específicamente la proteína tanto en líneas celulares como en tejidos humanos normales y tumorales usando métodos inmunológicos. Empleando estos anticuerpos, demostramos que la proteína se sobreexpresa en la mayoría de los adenocarcinomas de próstata humanos, por lo que la detección de este transcrito y proteína constituye un nuevo marcador de este tipo de tumores, con potencial utilidad en su diagnóstico. Esta proteína es además una proteína diana la identificación de compuestos para terapias antitumorales.New protein overexpressed in prostate cancer. A new gene and protein overexpressed in prostate cancer has been identified and sequenced. The present invention demonstrates that it is overexpressed in prostate adenocarcinoma using the RT-PCR and western-blot technique. The expression of this protein is correlated with the proliferation of tumors. Specific antibodies have been generated that specifically detect the protein both in cell lines and in normal and tumor human tissues using immunological methods. Using these antibodies, we demonstrate that the protein is overexpressed in most human prostate adenocarcinomas, so the detection of this transcript and protein constitutes a new marker of this type of tumors, with potential utility in its diagnosis. This protein is also a target protein identifying compounds for antitumor therapies.

ES200100592A 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA. Expired - Fee Related ES2180417B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200100592A ES2180417B1 (en) 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.
PCT/ES2002/000122 WO2002072633A1 (en) 2001-03-14 2002-03-14 Novel overexpressed protein in prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100592A ES2180417B1 (en) 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.

Publications (2)

Publication Number Publication Date
ES2180417A1 ES2180417A1 (en) 2003-02-01
ES2180417B1 true ES2180417B1 (en) 2004-05-16

Family

ID=8497077

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100592A Expired - Fee Related ES2180417B1 (en) 2001-03-14 2001-03-14 NEW OVEREXPRESSED PROTEIN IN CANCER DE PROSTATA.

Country Status (2)

Country Link
ES (1) ES2180417B1 (en)
WO (1) WO2002072633A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067560A2 (en) * 2003-01-27 2004-08-12 Gsf - Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Herpes simplex vp16 protein binding polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506020A (en) * 1999-07-21 2003-02-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 25 human prostate proteins and prostate cancer-related proteins
GB9917725D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides

Also Published As

Publication number Publication date
WO2002072633A1 (en) 2002-09-19
ES2180417A1 (en) 2003-02-01

Similar Documents

Publication Publication Date Title
Garate et al. The NAD (P) H: Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells
Beckenkamp et al. DPPIV/CD26: a tumor suppressor or a marker of malignancy?
MX2010000405A (en) Drug selection for lung cancer therapy using antibody-based arrays.
CY1116967T1 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT AND DIAGNOSIS
CY1110256T1 (en) TRANSMISSIONAL CYCLE TRANSMISSIONAL LIGGIN ANTIGEN IN HUMAN PROTECTOR AND HIS USE
WO2003106974A3 (en) Diagnosis and treatment of chemoresistant tumors
Zienert et al. LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells
Cashman et al. SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
CY1115178T1 (en) CANCER INDUSTRIES
CY1110029T1 (en) GENDER EXPRESSIVED IN PROTECTIVE CANCER
AU1726199A (en) Metastatic cancer regulated gene
Warta et al. Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients
HK1148783A1 (en) Gene expression markers for breast cancer prognosis
ATE444309T1 (en) IMMUNOTHERAPY FOR CRONIC MYELOCYTIC LEUKEMIA WITH NAKED ANTI-NCA-90 ANTIBODIES
MX351889B (en) Anti-cxcr1 compositions and methods.
WO2004000094A3 (en) Predictive markers in cancer therapy
NO20090174L (en) Gene family (LBFL313) associated with pancreatic cancer
Schirmer et al. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
Jin et al. Aberrant methylation of the Ras-related associated with diabetes gene in human primary esophageal cancer
Ozawa et al. Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma
Yu et al. MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma
ATE350662T1 (en) MARKER PROTEINS FOR PROSTATE CANCER
Ning et al. Molecular functions and significance of the MTA family in hormone-independent cancer

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030201

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2180417B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807